08:30-10:00

Guangdong Hall I

Leading Forum The growing era of inflammatory bowel disease

Chair

*(BA02) Guselkumab induction therapy effect on endoscopic outcome measures in moderately-to-severely active Crohn’s disease patients: week-12 results from phase-2 GALAXI-1 study

(BA02) Guselkumab induction therapy effect on endoscopic outcome measures in moderately-to-severely active Crohn’s disease patients: week-12 results from phase-2 GALAXI-1 study

09:45-10:00

Guangdong Hall I

Leading Forum The growing era of inflammatory bowel disease

Speaker

*Risk of COVID-19 infection in patients with inflammatory bowel disease

10:30-10:50

Guangdong Hall I

COVID-19 Forum COVID-19: experience is the record of mistakes

Speaker

*The ultimate therapeutic goal in IBD and how to achieve it

12:20-12:30

Guangdong Hall I

Lunch Symposium I

Speaker

*Case Sharing 1

12:30-12:40

Guangdong Hall I

Lunch Symposium I

Speaker

Panel Discussion

12:55-13:05

Guangdong Hall I

Lunch Symposium I

Discussant

*Small molecules: current position in treatment strategies for inflammatory bowel disease

13:30-13:50

Guangdong Hall III

New Therapy Forum Novel therapeutic targets by biologics and small molecules

Speaker